Gemcitabine, alone or in combination with cisplatin, in patients with advanced or metastatic cholangiocarcinomas and other biliary tract tumours

ISRCTN ISRCTN96194255
DOI https://doi.org/10.1186/ISRCTN96194255
Secondary identifying numbers 1348
Submission date
12/05/2010
Registration date
12/05/2010
Last edited
10/09/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Juan Valle
Scientific

Department of Medical Oncology
550 Wilmslow Road
Manchester
M20 4BX
United Kingdom

Study information

Study designMulticentre randomised interventional treatment trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Other
Study typeTreatment
Participant information sheet Not available in web format, please contact Juan.Valle@christie.nhs.uk to request a patient information sheet
Scientific titleGemcitabine, alone or in combination with cisplatin, in patients with advanced or metastatic cholangiocarcinomas and other biliary tract tumours: a multicentre, randomised phase II study
Study acronymABC-01
Study objectivesThere is no standard chemotherapy for patients with advanced biliary tract cancer. Gemcitabine has shown some activity in early phase II studies. Cisplatin is known to synergise with gemcitabine in other tumour types (including lung, head and neck and bladder cancers). The specific sequence of cisplatin followed by gemcitabine appears optimal in pre-clinical testing. Cisplatin/gemcitabine combinations have been reported in pancreatic cancer in various schedules and we have completed a phase I/II study of weekly co-administration of both drugs in advanced pancreatic cancer demonstrating good tolerability.

The aim of this study was to examine this regimen in biliary tumours using a randomised phase II study of gemcitabine as a single agent and the cisplatin/gemcitabine combination. Before undertaking a full phase III trial in comparison with other regimens (or best supportive care) this study assessed the relative merits of each treatment arm in terms of efficacy, feasibility and tolerability.
Ethics approval(s)NorthWest MREC approved on the 2nd August 2002 (ref: 02/8/32)
Health condition(s) or problem(s) studiedTopic: National Cancer Research Network; Subtopic: Upper Gastro-Intestinal Cancer; Disease: Biliary Tract, Gall Bladder
InterventionThis was an investigator-led, multicentre, randomised phase II study of weekly (3 weeks in every 4, x 6 cycles) of gemcitabine IV 1000 mg/m2 as a single agent (control) or preceded by cisplatin IV 25 mg/m2 (on a 2 weeks in every 3-cycle, x 8 cycles) in patients with histologically proven, inoperable or metastatic cholangiocarcinoma or other biliary tract tumours not previously treated with chemotherapy.

A minimum of 2 cycles was required to assess tumour status and the maximum period of therapy was 24 weeks (six 4-weekly cycles of single agent gemcitabine, eight 3-weekly cycles of cisplatin/gemcitabine). Assessment by CT scan every 12 weeks during treatment was used to determine tumour status.

Study entry: Single randomisation only
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase II
Drug / device / biological / vaccine name(s)Gemcitabine, cisplatin
Primary outcome measureTo assess the efficacy in terms of 6-month progression-free rate for both treatment arms
Secondary outcome measures1. Overall survival
2. Response rate, evaluated after 12 and 24 weeks of treatment via CT, according to WHO guidelines
3. Toxicity assessment (adverse events [AEs] graded according to National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] criteria)
Overall study start date11/01/2002
Completion date14/05/2004

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexNot Specified
Target number of participantsPlanned sample size: 86; UK sample size: 86
Key inclusion criteria1. Histologically or cytologically verified, non-resectable or recurrent/metastatic cholangiocarcinoma (intra- or extra-hepatic), gallbladder or ampullary carcinoma
2. Measurable, non-measurable or evaluable disease on computed tompgraphy (CT) or magnetic resonance (MR) scanning. Radiological assessments must be done within 4 weeks of starting chemotherapy.
3. Karnofsky performance status greater or equal to 60
4. Age greater than or equal to 18 years, either sex
5. Life expectancy greater than 3 months
6. Adequate renal function with serum urea and serum creatinine less than 1.5 times upper limit of normal (ULN) and glomerular filtration rate greater or equal to 60 ml/min as measured by creatinine clearance or EDTA or calculated by using the Cockroft formula
7. Adequate haematological function:
7.1. Haemoglobin greater or equal to 10 g/dl
7.2. White blood cell count (WBC) greater or equal to 3.0 x 10^9/L
7.3. Absolute neutrophil count (ANC) greater or equal to 1.5 x 10^9/L
7.4. Platelet count greater or equal to 100,000/mm^3
8. Adequate liver function:
8.1. Total bilirubin less than 30 mmol/L
8.2. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase less than or equal to 3 x ULN (unless liver metastases are present, when they can be less than or equal to 5 x ULN)
9. Adequate biliary drainage, with no evidence of ongoing infection
10. Women of child bearing age MUST have a negative pregnancy test prior to study entry AND be using an adequate contraception method, which must be continued for 3 months after the study, unless child bearing potential has been terminated by surgery/radical radiotherapy
11. Previous radiotherapy (or chemo-radiotherapy) is allowed, as long as the measurable disease to be evaluated in this study does not fall within the previous radiotherapy treatment field
12. Prior photodynamic therapy is allowed, provided there has been clear radiological evidence of disease progression
13. Patients must not have a history of other malignant diseases other than adequately treated non-melanotic skin cancer or in-situ carcinoma of the uterine cervix
14. Patients must have given written informed consent
Key exclusion criteria1. Incomplete recovery from previous surgery or unresolved biliary tree obstruction
2. Any previous chemotherapy (with the exception of low-dose chemotherapy used as a radiosensitiser during combined modality chemo-radiotherapy)
3. Previous investigational agent in the last 12 weeks
4. Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator, makes it undesirable for the patient to participate in the trial
5. Evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator makes it undesirable for the patient to participate in the trial
6. Any patient with a medical or psychiatric condition that impairs their ability to give informed consent
7. Any other serious uncontrolled medical conditions
8. Clinical evidence of metastatic disease to brain
9. Any pregnant or lactating woman
Date of first enrolment11/01/2002
Date of final enrolment14/05/2004

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Department of Medical Oncology
Manchester
M20 4BX
United Kingdom

Sponsor information

Christie Hospital NHS Foundation Trust (UK)
Hospital/treatment centre

550 Wilmslow Road
Manchester
M20 4BX
England
United Kingdom

Website http://www.christie.nhs.uk/
ROR logo "ROR" https://ror.org/03v9efr22

Funders

Funder type

Industry

Lilly Oncology (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 18/08/2009 Yes No

Editorial Notes

10/09/2019: Internal review.